Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer
US10688180B2 · kind B2 · utility
1Cited by
1References
15Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Sep 13, 2017 |
| Grant date | Jun 23, 2020 |
| Priority date | — |
| Expiry date | Oct 12, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are methods for clinical treatment of cancer (e.g., solid tumors or hematological malignancies) using an anti-KIR antibody in combination with an anti-CTLA-4 antibody.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.